Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Daily life participation in childhood chronic disease: a qualitative study.

Nap-van der Vlist MM, Kars MC, Berkelbach van der Sprenkel EE, Nijhof LN, Grootenhuis MA, van Geelen SM, van der Ent CK, Swart JF, van Royen-Kerkhof A, van Grotel M, van de Putte EM, Nijhof SL.

Arch Dis Child. 2019 Nov 20. pii: archdischild-2019-318062. doi: 10.1136/archdischild-2019-318062. [Epub ahead of print]

PMID:
31748222
2.

Fatigue in childhood chronic disease.

Nap-van der Vlist MM, Dalmeijer GW, Grootenhuis MA, van der Ent CK, van den Heuvel-Eibrink MM, Wulffraat NM, Swart JF, van Litsenburg RRL, van de Putte EM, Nijhof SL.

Arch Dis Child. 2019 Nov;104(11):1090-1095. doi: 10.1136/archdischild-2019-316782. Epub 2019 Jun 7.

PMID:
31175124
3.

Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.

Ramanan AV, Hampson LV, Lythgoe H, Jones AP, Hardwick B, Hind H, Jacobs B, Vasileiou D, Wadsworth I, Ambrose N, Davidson J, Ferguson PJ, Herlin T, Kavirayani A, Killeen OG, Compeyrot-Lacassagne S, Laxer RM, Roderick M, Swart JF, Hedrich CM, Beresford MW.

PLoS One. 2019 Jun 5;14(6):e0215739. doi: 10.1371/journal.pone.0215739. eCollection 2019.

4.

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients.

Swart JF, de Roock S, Nievelstein RAJ, Slaper-Cortenbach ICM, Boelens JJ, Wulffraat NM.

Rheumatology (Oxford). 2019 Oct 1;58(10):1812-1817. doi: 10.1093/rheumatology/kez157.

5.

Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review.

Kip MMA, Currie G, Marshall DA, Grazziotin Lago L, Twilt M, Vastert SJ, Swart JF, Wulffraat N, Yeung RSM, Benseler SM, IJzerman MJ; UCAN CAN-DU Health Economics Working Group.

Pediatr Rheumatol Online J. 2019 May 6;17(1):20. doi: 10.1186/s12969-019-0321-x. Review.

6.

Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.

Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, de Jager W, de Groot MCH, Haitjema S, Holzinger D, Foell D, van Loosdregt J, Wulffraat NM, de Roock S, Vastert SJ.

Arthritis Rheumatol. 2019 Jul;71(7):1163-1173. doi: 10.1002/art.40865. Epub 2019 May 25.

7.

Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.

Doeleman MJH, van Maarseveen EM, Swart JF.

Rheumatology (Oxford). 2019 Oct 1;58(10):1839-1849. doi: 10.1093/rheumatology/kez030.

8.

Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol.

Schoemaker CG, Armbrust W, Swart JF, Vastert SJ, van Loosdregt J, Verwoerd A, Whiting C, Cowan K, Olsder W, Versluis E, van Vliet R, Fernhout MJ, Bookelman SL, Cappon J, van den Berg JM, Schatorjé E, Muller PCEH, Kamphuis S, de Boer J, Lelieveld OTHM, van der Net J, Jongsma KR, van Rensen A, Dedding C, Wulffraat NM.

Pediatr Rheumatol Online J. 2018 Sep 15;16(1):57. doi: 10.1186/s12969-018-0276-3. Review.

9.

Treating juvenile idiopathic arthritis to target: recommendations of an international task force.

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.

Ann Rheum Dis. 2018 Jun;77(6):819-828. doi: 10.1136/annrheumdis-2018-213030. Epub 2018 Apr 11.

PMID:
29643108
10.

The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Dehoorne J, Joos R, Wouters C, Swart JF, Consolaro A, Bovis F, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Apr;38(Suppl 1):187-194. doi: 10.1007/s00296-018-3935-2. Epub 2018 Apr 7.

11.

The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Wulffraat N, Kamphuis S, Swart JF, Vastert S, Van Dijkhuizen P, van Pelt P, van Dijk-Hummelman A, Consolaro A, Bovis F, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Apr;38(Suppl 1):139-146. doi: 10.1007/s00296-018-3971-y. Epub 2018 Apr 7.

12.

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.

Swart JF, van Dijkhuizen EHP, Wulffraat NM, de Roock S.

Ann Rheum Dis. 2018 Mar;77(3):336-342. doi: 10.1136/annrheumdis-2017-212104. Epub 2017 Nov 14.

13.

Haematopoietic stem cell transplantation for autoimmune diseases.

Swart JF, Delemarre EM, van Wijk F, Boelens JJ, Kuball J, van Laar JM, Wulffraat NM.

Nat Rev Rheumatol. 2017 Apr;13(4):244-256. doi: 10.1038/nrrheum.2017.7. Epub 2017 Feb 23. Review.

PMID:
28228650
14.

Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype.

Swart JF, de Roock S, Prakken BJ.

Eur J Immunol. 2016 Sep;46(9):2068-77. doi: 10.1002/eji.201546092. Review.

15.

Mesenchymal stromal cells for treatment of arthritis.

Swart JF, Wulffraat NM.

Best Pract Res Clin Rheumatol. 2014 Aug;28(4):589-603. doi: 10.1016/j.berh.2014.10.023. Epub 2014 Oct 30. Review.

PMID:
25481552
16.

Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis.

van den Broek T, Hoppenreijs E, Meerding J, Scholman R, Otten HG, Swart JF, Martini A, Prakken B, de Jager W.

Ann Rheum Dis. 2015 Feb;74(2):470-2. doi: 10.1136/annrheumdis-2014-206424. Epub 2014 Nov 10. No abstract available.

PMID:
25384964
17.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.

PMID:
24641940
18.

Mesenchymal stem cell therapy in proteoglycan induced arthritis.

Swart JF, de Roock S, Hofhuis FM, Rozemuller H, van den Broek T, Moerer P, Broere F, van Wijk F, Kuis W, Prakken BJ, Martens AC, Wulffraat NM.

Ann Rheum Dis. 2015 Apr;74(4):769-77. doi: 10.1136/annrheumdis-2013-204147. Epub 2014 Jan 6.

PMID:
24395558
19.

Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?

van Royen-Kerkhof A, Vastert BS, Swart JF, Wulffraat NM.

Immunotherapy. 2014;6(1):1-3. doi: 10.2217/imt.13.153. No abstract available.

20.

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Sep;52(9):1674-9. doi: 10.1093/rheumatology/ket170. Epub 2013 Jun 4.

PMID:
23740187
21.
22.

Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.

Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Apr;52(4):712-7. doi: 10.1093/rheumatology/kes373. Epub 2012 Dec 24.

PMID:
23267169
23.

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.

Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

Ann Rheum Dis. 2013 May;72(5):721-7. doi: 10.1136/annrheumdis-2011-201060. Epub 2012 Jun 23.

PMID:
22730374
24.

Changing winds in refractory autoimmune disease in children: clearing the road for tolerance with cellular therapies.

Swart JF, Lindemans CA, van Royen A, Boelens JJ, Prakken BJ, Wulffraat N.

Curr Opin Rheumatol. 2012 May;24(3):267-73. doi: 10.1097/BOR.0b013e32835264f4. Review.

PMID:
22418744
25.

Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a Web-based survey.

Haverman L, Grootenhuis MA, van den Berg JM, van Veenendaal M, Dolman KM, Swart JF, Kuijpers TW, van Rossum MA.

Arthritis Care Res (Hoboken). 2012 May;64(5):694-703. doi: 10.1002/acr.21609.

26.

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

JAMA. 2011 Dec 7;306(21):2340-7. doi: 10.1001/jama.2011.1671. Epub 2011 Nov 6.

PMID:
22056397
27.

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.

J Rheumatol. 2011 Oct;38(10):2258-63. doi: 10.3899/jrheum.110145. Epub 2011 Aug 15.

PMID:
21844151
28.

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.

Swart JF, Barug D, Möhlmann M, Wulffraat NM.

Expert Opin Biol Ther. 2010 Dec;10(12):1743-52. doi: 10.1517/14712598.2010.532785. Epub 2010 Oct 28. Review.

PMID:
20979564
29.

Diagnostic workup for mixed connective tissue disease in childhood.

Swart JF, Wulffraat NM.

Isr Med Assoc J. 2008 Aug-Sep;10(8-9):650-2. Review.

30.

No structural cerebral differences between children with a history of bacterial meningitis and healthy siblings.

de Jonge RC, Swart JF, Koomen I, Rombouts SA, Gemke RJ, Barkhof F, van Furth AM.

Acta Paediatr. 2008 Oct;97(10):1390-6. doi: 10.1111/j.1651-2227.2008.00944.x. Epub 2008 Jul 11.

PMID:
18637795
31.

[Two children with arthritis and uveitis: the clinical importance of ophthalmologic screening in children with juvenile arthritis].

Sijssens KM, Swart JF, de Boer JH.

Ned Tijdschr Geneeskd. 2006 Oct 21;150(42):2289-93. Dutch.

PMID:
17089543
32.

Rectal bleeding in a preterm infant as a symptom of allergic colitis.

Swart JF, Ultee K.

Eur J Pediatr. 2003 Jan;162(1):55-6. No abstract available.

PMID:
12607535
33.

Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome.

Swart JF, de Kraker J, van der Lely N.

Eur J Pediatr. 2002 May;161(5):255-8. Epub 2002 Mar 13.

PMID:
12012219

Supplemental Content

Loading ...
Support Center